CD244 and neoplasm: On the other hand, Slamf4 receptor (also known as CD244) positivity in MDSCs correlates with their inhibitory function in antitumor immunity23, supporting the idea that the lytC_22–Slamf4 interaction functionally activates MDSCs to impair T cells in the CRC tumour immune microenvironment.